HOME | PRODUCTS | OSTEOPOROSIS | Otosclerosis| BIOTINIDASE DEFICIENCY | RESEARCH | CONTACT US | PRIVACY POLICY

 

Monofouorophosphate plus Calcium for Postmenopausal Osteoporosis Fig. 3

Individual patients

Group A( F 15 mg interm.) Group B( F 20 mg cont.) Group C (Ca only
n=31 n=30 n=33
Average change of BMD: Average change of BMD: Average change of BMD:
L2-L4: 12.6% L2-L4: 19.5% L2-L4: -1.6%
Femur neck: 2.3% Femur neck –1.8% Femur neck: -6.35%
  Fig. 3 Individual changes in BMD at the lumbar and femoral neck after 3 years of treatment  
(patients are sorted from left to right according to increasing average BMD at lumbar spine).

 

These statement on mericon-industries.com have not been evaluated by the Food and Drug Administration. The products and research on this website are not intended to diagnose, treat or cure or prevent disease.

 

Mericon Industries, Inc

All Rights Reserved 1998-2010